Am J Hematol

1. YUEN S, Phillips TJ, Bannerji R, Marlton P, et al
   Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
   Am J Hematol. 2024 May 3. doi: 10.1002/ajh.27341.
   

   >> Share

   
   

   
   Blood

2. HILTON LK, Collinge BJ, Ben-Neriah S, Alduaij W, et al
   Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study.
   Blood. 2024 May 3:blood.2024024251. doi: 10.1182/blood.2024024251.
   

   >> Share

   
   
3. KIM J, Cho J, Lee MH, Yoon SE, et al
   Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis.
   Blood. 2024 May 2:blood.2023023419. doi: 10.1182/blood.2023023419.
   

   >> Share

   
   
4. ARORA J, Ayyappan S, Yin C, Smith BJ, et al
   T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
   Blood. 2024;143:1816-1824.
   

   >> Share

   
   

   
   Br J Haematol

5. KUCZMARSKI TM, Lynch RC
   Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphoma.
   Br J Haematol. 2024 May 2. doi: 10.1111/bjh.19478.
   

   >> Share

   
   
6. VANDTVED JH, Ovlisen AK, Baech J, Weinrich UM, et al
   Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study.
   Br J Haematol. 2024 Apr 29. doi: 10.1111/bjh.19475.
   

   >> Share

   
   

   
   Haematologica

7. RENAUD L, Wencel J, Pages A, Al Jijakli A, et al
   Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.
   Haematologica. 2024 May 2. doi: 10.3324/haematol.2023.284689.
   

   >> Share

   
   

   
   Leuk Lymphoma

8. HUNTINGTON SF, Cheng WY, Sarpong EM, Leng S, et al
   Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
   Leuk Lymphoma. 2024 May 2:1-11. doi: 10.1080/10428194.2024.2331631.
   

   >> Share

   
   

   
   Leukemia

9. FISCHER L, Jiang L, Durig J, Schmidt C, et al
   The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
   Leukemia. 2024 Apr 27. doi: 10.1038/s41375-024-02254.
   

   >> Share

   
   

   
   PLoS One

10. BIJOU I, Liu Y, Lu D, Chen J, et al
    Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma.
    PLoS One. 2024;19:e0289902.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share